Philipp Rubenbauer

USPTO Granted Patents = 9 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 5(Granted Patents)

Location History:

Düsseldorf, DE (2019)
Dusseldorf, DE (2019 - 2020)
Bensheim, DE (2020 - 2022)

Company Filing History:

7 out of 378

Bayer Pharma Aktiengesellschaft

patents

4 out of 12,157

Bayer Aktiengesellschaft

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258343 - Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (2025-03-25),

2. 11365179 - Method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone (2022-06-21),

3. 11344519 - Orally administrable modified-release pharmaceutical dosage form (2022-05-31),

4. 11332435 - Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient (2022-05-17),

5. 10905667 - Orally administrable modified-release pharmaceutical dosage form (2021-02-02),

6. 10703742 - Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives (2020-07-07),

7. 10676443 - Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile (2020-06-09),

8. 10494372 - Synthesis of copanlisib and its dihydrochloride salt (2019-12-03),

9. 10316001 - Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrohydro pyrimidine-5-carbonitrile (2019-06-11),

Title: Innovator Spotlight: Philipp Rubenbauer

Introduction: Philipp Rubenbauer, an accomplished inventor hailing from Bensheim, Germany, has made significant contributions to the field of pharmaceuticals. With a total of 8 patents to his name, his work demonstrates a commitment to advancing medical science through innovative solutions.

Latest Patents: Rubenbauer's recent inventions include a method for the preparation of a 2,4,5-trisubstituted 1,2,4-triazolone. This patent outlines a method for synthesizing Compound (I), along with the use of intermediates for its preparation and its crystalline form A. Additionally, he has developed an orally administrable modified-release pharmaceutical dosage form. This invention encompasses dosage forms containing sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate, aimed at treating and preventing various disorders, including cardiac, renal, and pulmonary issues, as well as conditions related to the central nervous system and metabolic disorders.

Career Highlights: Rubenbauer has a distinguished career, having worked with prominent companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His experience in these leading pharmaceutical firms has undoubtedly shaped his innovative approach and strengthened his ability to bring impactful inventions to life.

Collaborations: Throughout his career, Rubenbauer has collaborated with talented individuals like Heiko Schirmer and Britta Olenik. Their collective expertise and creativity in their respective fields have contributed to the successful development of groundbreaking pharmaceutical solutions.

Conclusion: Philipp Rubenbauer exemplifies the spirit of innovation in the pharmaceutical industry. His extensive patent portfolio reflects his dedication to improving medical treatments and showcases his position as a leading inventor in the field. As he continues to develop new technologies and approaches, his work will undoubtedly leave a lasting impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.